BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 20,500 Shares

Key Points

• CEO Ugur Sahin sold 20,500 BioNTech shares at an average price of $96.31, generating $1.97 million. The transaction occurred under a pre-arranged Rule 10b5-1 plan, reducing his direct holdings by 2.89% to 688,209 shares.
• BioNTech shares rose 0.3% to $96.73, while the company reported weak quarterly results: a loss of $2.53 per share versus the expected $2.40 loss and revenue of $122.31 million, down 59.5% year over year.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and a $126 average price target, despite some recent downgrades. Institutional investors own 15.52% of BioNTech’s stock.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 20,500 shares of the company's stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $96.31, for a total value of $1,974,355.00. Following the completion of the transaction, the chief executive officer directly owned 688,209 shares of the company's stock, valued at $66,281,408.79. This represents a 2.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total transaction of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Trading Up 0.3%

NASDAQ BNTX traded up $0.33 on Friday, hitting $96.73. The company's stock had a trading volume of 1,176,224 shares, compared to its average volume of 1,110,613. The company's 50-day moving average is $97.00 and its 200 day moving average is $95.37. The firm has a market cap of $24.46 billion, a PE ratio of -12.35 and a beta of 1.29. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). The business had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.BioNTech's revenue for the quarter was down 59.5% on a year-over-year basis. During the same quarter last year, the firm posted ($1.60) EPS. As a group, analysts predict that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on BNTX shares. UBS Group raised BioNTech from a "neutral" rating to a "buy" rating and increased their price target for the company from $117.00 to $135.00 in a research note on Wednesday, May 27th. Canaccord Genuity Group cut their price objective on BioNTech from $142.00 to $136.00 and set a "buy" rating on the stock in a research note on Monday, August 31st. Wall Street Zen cut BioNTech from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Morgan Stanley decreased their target price on shares of BioNTech from $126.00 to $119.00 and set an "overweight" rating for the company in a research report on Wednesday, July 8th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of BioNTech in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BioNTech currently has an average rating of "Moderate Buy" and a consensus price target of $126.00.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Larson Financial Group LLC boosted its position in shares of BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company's stock valued at $26,000 after purchasing an additional 127 shares in the last quarter. EFG International AG bought a new stake in BioNTech in the fourth quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd increased its holdings in BioNTech by 520.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company's stock worth $30,000 after purchasing an additional 260 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in BioNTech in the second quarter valued at approximately $39,000. Finally, Tower Research Capital LLC TRC lifted its stake in BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock valued at $60,000 after buying an additional 305 shares during the period. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.